Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesArgent Biopharma Ltd

Argent Biopharma Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.019 AUD 0.00(0%)
Last update at 2026-11-11T23:03:00Z
VOLUME
15157
Market Cap
2.59M

Momentum Score

…

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnicann for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound management. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.02
Low
0.09
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Argent Biopharma Ltd (ASX: RGT) is an Australian small-cap biopharmaceutical company; public information on its pipeline and development stage is limited. Long-term growth may be driven by clinical progress, regulatory approvals, licensing or partnering deals, and successful commercialization, which could provide milestone and royalty upside for investors.

Material risks include an unproven pipeline with binary clinical and regulatory outcomes, substantial financing and dilution risk, and limited liquidity of shares.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
0.16M
Revenue Per Share
0.00
Gross Profit TTM
-0.04M
Debt / Equity
-1.02
ROE
-307.40%
Net Debt
9.45M
ROCE
102.03%
Diluted EPS TTM
-0.09

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -7.71M -17.84M -17.55M -21.13M -20.77M
Minority interest - - 0.02M 0.31M 0.37M
Net income -7.71M -17.84M -17.53M -20.82M -20.35M
Selling general administrative - 8.03M 8.67M 13.86M 10.82M
Selling and marketing expenses - 0.02M 2.42M 0.93M 1.01M
Gross profit -0.20M 0.45M 0.20M 0.70M 1.56M
Reconciled depreciation - 0.79M 1.29M 0.49M 0.50M
Ebit -7.39M -17.79M -17.07M -15.49M -12.90M
Ebitda -7.23M -17.00M -15.77M -14.74M -12.50M
Depreciation and amortization 0.16M 0.79M 1.29M 0.75M 0.41M
Operating income -7.39M -15.44M -18.26M -15.49M -12.90M
Other operating expenses 7.55M 16.03M 19.15M 18.88M 17.64M
Interest expense 0.03M 0.05M 0.48M 0.26M 0.21M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.00M 0.00M 0.34M 0.00M
Net interest income - -0.05M -0.48M -0.34M -0.19M
Income tax expense - - - 0.00M -0.42M
Total revenue 0.16M 0.58M 0.89M 3.39M 4.73M
Total operating expenses 7.19M 15.89M 18.47M 16.19M 14.47M
Cost of revenue 0.37M 0.14M 0.69M 2.69M 3.17M
Total other income expense net -0.32M -2.40M 0.71M -5.64M -7.86M
Net income from continuing ops - -17.84M -17.55M -21.13M -17.14M
Net income applicable to common shares - - - -20.82M -16.77M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 1.29M 2.47M 10.79M 9.98M 18.56M
Intangible assets - - - 0.00M 3.15M
Other current assets 0.08M - - 0.40M 0.80M
Total liab 10.74M 11.10M 16.61M 18.02M 13.38M
Total stockholder equity -9.45M -8.63M -5.15M -7.40M 5.84M
Other current liab 0.39M - 8.68M 1.12M 1.00M
Common stock 140.69M - - 103.69M 97.25M
Capital stock - 138.59M 123.29M 103.71M 97.44M
Retained earnings -155.22M -147.51M -129.67M -119.17M -98.35M
Other liab - - - 4.30M 2.38M
Good will - - - - 3.15M
Other assets - - - 0.00M 0.16M
Cash 0.14M 1.02M 0.70M 0.24M 1.89M
Total current liabilities 8.54M 10.83M 12.18M 13.33M 7.71M
Current deferred revenue - - - 0.66M 1.81M
Net debt 9.45M 6.91M - 9.51M 2.47M
Short term debt 7.39M - - 9.37M 2.38M
Short long term debt - 7.93M - - 2.10M
Short long term debt total 9.59M - - 9.75M 4.35M
Other stockholder equity - - - 0.21M 0.00M
Property plant equipment - - - 7.45M 9.70M
Total current assets 0.46M 2.03M 2.74M 2.53M 6.46M
Long term investments - - 1.33M - 0.16M
Net tangible assets - - - -7.40M 6.23M
Net receivables 0.24M 0.07M 0.14M 0.53M 1.94M
Inventory - 0.13M 0.88M 1.36M 1.84M
Accounts payable 0.76M 1.81M 0.96M 2.19M 2.52M
Accumulated other comprehensive income 5.09M - - 8.08M 6.93M
Non currrent assets other - - - -7.45M -12.10M
Non current assets total 0.84M 0.44M 8.05M 7.45M 12.10M
Capital lease obligations - 0.36M 1.04M 0.58M 2.29M
Long term debt total - - - 0.38M 2.14M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 0.21M -0.14M 0.05M -2.44M
Change to liabilities - - - 0.19M 1.63M
Total cashflows from investing activities -0.00M 0.21M -0.14M 0.61M -2.44M
Net borrowings - -0.20M - 6.96M -0.26M
Total cash from financing activities 3.14M 9.39M 14.87M 9.73M 9.74M
Net income -7.71M -17.84M -17.53M -20.82M -20.35M
Change in cash -0.88M 0.32M 0.46M -1.65M -3.55M
Begin period cash flow 1.02M 0.70M 0.24M 1.89M 5.43M
End period cash flow 0.14M 1.02M 0.70M 0.24M 1.89M
Total cash from operating activities -4.03M - - -11.99M -12.16M
Issuance of capital stock - 10.40M 15.70M 2.70M 10.76M
Depreciation 0.16M - - 0.75M 0.41M
Other cashflows from investing activities - 0.21M - 0.80M 1.58M
Dividends paid - - - 9.62M 9.24M
Change to inventory 0.13M - - 0.48M -0.97M
Change to account receivables 0.55M - - 1.41M 1.29M
Sale purchase of stock - - -0.60M -0.32M -0.76M
Other cashflows from financing activities -0.12M -0.81M -0.24M 14.45M 0.62M
Change to netincome - - - 6.02M 5.94M
Capital expenditures 0.00M 0.00M 0.14M 0.19M 2.69M
Change in working capital 0.01M - - 2.07M 1.96M
Stock based compensation - - - 2.66M 0.64M
Other non cash items 3.51M - - 5.45M 4.67M
Free cash flow -4.03M -9.28M -14.40M -12.18M -14.85M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RGT
Argent Biopharma Ltd		 -
-%		 0.02 - 14.37 16.09 9.85 74.69 -1.62
AFP
Aft Pharmaceuticals Ltd		 0.05
1.41%		 3.60 29.92 18.18 1.48 4.37 2.05 18.56
VLS
Vita Life Sciences Ltd		 0.09
3.42%		 2.72 13.50 42.73 1.52 2.62 1.19 7.17
LGP
Little Green Pharma Ltd		 0.01
16.67%		 0.07 - 10.00 0.64 0.60 1.25 19.47
MVP
Medical Developments International Ltd		 -
-%		 0.44 40.00 166.67 1.06 0.79 0.57 7.45

Profile*

Argent Biopharma Ltd

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnicann for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound management. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

295 Rokeby Road, Subiaco, WA, Australia, 6008

61 8 6555 2950

https://argentbiopharma.com

Name Title Year Born
Mr. Roby Reuven Zomer Co-Founder, CEO, MD & Executive Director 1980
Mr. Tom Cairns Chief Accounting Officer NA
Ms. Yifat Steuer Deputy CEO & COO NA
Ms. Nicole Ann Godresse Global Chief Sales Officer NA
Mr. Amir Polak Chief Pharmaceutical Development Officer NA
Ms. Sabina Suljakovic Head of the Quality Assurance Department NA
Dr. Nadya Lisovoder Chief Medical Officer NA
Ms. Sasha Friedman Deputy CEO NA
Yair Tal Chief Information Security Officer NA
Mr. Robert Clements Chief Commercial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…